Kyntra Bio receives final $4M from AstraZeneca, completing $220M China sale

Filed June 9, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

• high

  Company collected final $4.0 million holdback payment from AstraZeneca on June 2, completing all financial obligations from the August 2025 sale of China operations for total consideration of approximately $220 million.

  Item 8.01 verify on EDGAR →
• medium

  No indemnity claims were made against the holdback amount, allowing full release of funds. Original sale included $85 million in enterprise value plus approximately $135 million in net cash held in China.

  Item 8.01 verify on EDGAR →
• medium

  Transaction timeline: $210 million received at August 2025 closing, $6.4 million in November 2025, and final $4.0 million in June 2026, marking complete divestiture of China operations to AstraZeneca.

  Item 8.01 verify on EDGAR →